• Clinical Insights: September 14, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval No new update. New Formulation Approval No new update. New Indication/Dosage Approval No new update. New/Updated Drug Shortage September 10, 2021 Atropine Sulfate Injection (Currently in Shortage) Bacitracin… Read more »

  • Clinical Insights: September 8, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Trudhesa™ (dihydroergotamine mesylate) Nasal Spray – New Drug Approval – September 3, 2021 –  Impel NeuroPharma, Inc., a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from… Read more »

  • Clinical Insights: August 31, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Tibsovo® (ivosidenib) – New Drug Approval – August 25, 2021 – The Food and Drug Administration approved ivosidenib (Tibsovo®, Servier Pharmaceuticals LLC) for adult patients with previously treated,… Read more »

  • Clinical Insights: August 24, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Comirnaty™ (Pfizer-BioNTech COVID-19 Vaccine) – New Vaccine Approval – August 23, 2021 – The U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been… Read more »

  • Clinical Insights: August 17, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Welireg™ (belzutifan) Tablets – New Drug Approval – August 13, 2021 – The Food and Drug Administration approved belzutifan (Welireg™, Merck), a hypoxia-inducible factor inhibitor for adult patients with… Read more »

  • Clinical Insights: August 10, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Nexviazyme® (avalglucosidase alfa-ngpt) Intravenous Infusion – New Orphan Drug Approval – August 6, 2021 – The U.S. Food and Drug Administration approved Genzyme’s Nexviazyme® (avalglucosidase alfa-ngpt) for intravenous… Read more »

  • Celebrate National Health Center Week 2021

    At RxStrategies, we are so grateful for the support and quality care provided by Community Health Centers across the U.S. and are honored to support their efforts. With the continued impact of the COVID-19 pandemic, we recognize the health care professionals on the front-line who are the chemistry for our strong communities. Learn more about… Read more »

  • Clinical Insights: August 3, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Twyneo® (tretinoin and benzoyl peroxide) Cream – New Drug Approval – July 27, 2021 – Sol-Gel Technologies, Ltd., a dermatology company focused on identifying, developing and commercializing branded and… Read more »

  • Clinical Insights: July 27, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Bylvay™ (odevixibat) Capsules – New Drug Approval – July 20, 2021 – Albireo Pharma, Inc., a rare liver disease company developing novel bile acid modulators, announced the U.S. Food… Read more »

  • Clinical Insights: July 20, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Rezurock™ (belumosudil) Tablets – New Drug Approval – July 16, 2021 – The Food and Drug Administration approved belumosudil (Rezurock™, Kadmon Pharmaceuticals, LLC), a kinase inhibitor, for adult and… Read more »